[EN] PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS [FR] PRÉPARATION ET SÉPARATION ÉNANTIOMÉRIQUE DE NONANE DE 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] ET NOUVELLES FORMES DE SEL DU RACÉMATE ET D'ÉNANTIOMÈRES
[EN] PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS [FR] PRÉPARATION ET SÉPARATION ÉNANTIOMÉRIQUE DE NONANE DE 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] ET NOUVELLES FORMES DE SEL DU RACÉMATE ET D'ÉNANTIOMÈRES
PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4]NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS
申请人:Beaver Jessica
公开号:US20110118239A1
公开(公告)日:2011-05-19
A novel scalable synthesis for the preparation of 7-(3-pyridinyI)-1,7-diazaspiro[4.4)nonane has been developed, and 7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane salts have been formed with succinic acid and oxalic acid. Additionally, 7-(3-pyridinyl)-1,7-diaza-spiro[4.4]nonane has been separated into its stereoisomers via resolution with L and D di-p-toluoyltartaric acids, giving (R)- and (S)-7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane of high enantiomeric purity. Numerous solid salts of the resulting (R)- and (S)-7-(3-pyridinyl)-1,7-diazaspiro[4.4}nonane have been prepared. Methods for the preparation of the racemic and enantiomeric salts, pharmaceutical compositions comprising such salts, and uses thereof are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.
[EN] N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF<br/>[FR] COMPOSES DIAZASPIROCYCLIQUES N-ARYLE ET PROCEDES DE PREPARATION ET D'UTILISATION DE CES DERNIERS
申请人:TARGACEPT INC
公开号:WO2004005293A3
公开(公告)日:2004-05-13
PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIROÝ4.4¨NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS
申请人:Targacept Inc.
公开号:EP2242364A1
公开(公告)日:2010-10-27
JP2011509933A
申请人:——
公开号:JP2011509933A
公开(公告)日:2011-03-31
[EN] PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS<br/>[FR] PRÉPARATION ET SÉPARATION ÉNANTIOMÉRIQUE DE NONANE DE 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] ET NOUVELLES FORMES DE SEL DU RACÉMATE ET D'ÉNANTIOMÈRES
申请人:TARGACEPT INC
公开号:WO2009091561A1
公开(公告)日:2009-07-23
A novel scalable synthesis for the preparation of 7-(3- pyridinyI)- 1,7- diazaspiro[4.4)nonane has been developed, and7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane salts have been formed with succinic acid and oxalic acid. Additionally, 7-(3-pyridinyl)-1,7- diazaspiro[4.4]nonane has been separated into its stereoisomers via resolution with L and D di-p-toluoyltartaric acids, giving (R)- and (S)-7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane of high enantiomeric purity. Numerous solid salts of the resulting (R)- and (S)-7-(3-pyridinyl)-1,7- diazaspiro[4.4}nonane have been prepared. Methods for the preparation of the racemic and enantiomeric salts, pharmaceutical compositions comprising such salts, and uses thereof are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.